Alessia Caldara - Publications

Prognostic value of post-neoadjuvant pathological response and residual disease in early breast cancer: a real-world cohort study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 02, 2026

Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.

Journal: Journal of clinical medicine

Published: May 09, 2024

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Journal: NPJ breast cancer

Published: February 05, 2024

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Journal: NPJ breast cancer

Published: October 31, 2023

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Journal: Seminars in oncology

Published: May 03, 2023

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Journal: NPJ breast cancer

Published: December 22, 2022

Whole Breast Irradiation Versus Intraoperative Electron Radiation Therapy for Breast Conserving Therapy: A Large Mature Single Institution Matched-Pair Evaluation of True Local Relapse, Progression Free Survival, and Overall Survival.

Journal: International journal of radiation oncology, biology, physics

Published: October 19, 2022

An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.

Journal: Cells

Published: September 03, 2022

Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Journal: ESMO open

Published: October 25, 2020

Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma.

Journal: Acta oncologica (Stockholm, Sweden)

Published: June 04, 2019

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 27, 2017

Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre.

Journal: Anti-cancer drugs

Published: March 03, 2017